Learn More
CD79a Monoclonal Antibody (24C2.5), eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
Brand: Affymetrix eBioscience 14-0791-82
Additional Details : Weight : 0.01000kg
Description
Description: This 24C2.5 monoclonal antibody reacts with the intracellular tail of mouse CD79a (also known as Ig alpha or mb-1), a signaling component of the B cell receptor (BCR). CD79a heterodimerizes with CD79b (Ig beta, B29), and together with surface Ig, make up the BCR. Both CD79 subunits consist of a single extracellular Ig domain, a transmembrane domain, and an intracellular signaling domain. CD79a is expressed almost exclusively on B cells, as well as in most B lineage acute lymphoblastic leukemias. The cytoplasmic domain of CD79a contains immunoreceptor tyrosine-based activation motifs (ITAMs), which constitute the signal transducing portions of the BCR. Tyrosine phosphorylation of these ITAMs by Syk and Lyn initiates numerous signaling cascades, resulting in B cell activation, proliferation, and differentiation. Applications Reported: This 24C2.5 antibody has been reported for use in immunoblotting (WB). Applications Tested: This 24C2.5 antibody has been tested by western blot of reduced mouse spleen lysates. This can be used at 1-10 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.
CD79a is a disulphide-linked heterodimer that includes B29 (CD79b) polypeptide. CD79a is a B lymphocyte antigen receptor with an antigen-specific surface component Ig (immunoglobulin) that associates with Ig-alpha and Ig-beta, necessary elements for the expression and function of the B-cell antigen receptor. CD79a first appears at pre-B cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Diseases associated with CD79a include Agammaglobulinemia 3 and Agammaglobulinemia, Non-Bruton type.Specifications
CD79a | |
Monoclonal | |
0.5 mg/mL | |
PBS with 0.09% sodium azide; pH 7.2 | |
P11911, P11912 | |
CD79A | |
Affinity chromatography | |
RUO | |
12518, 973 | |
4° C | |
Liquid |
Immunohistochemistry, Western Blot | |
24C2.5 | |
Unconjugated | |
CD79A | |
B-cell antigen receptor; B-cell antigen receptor complex-associated protein alpha chain; B-cell antigen receptor complex-associated protein alpha chain-like; CD79; CD79a; CD79A antigen (immunoglobulin-associated alpha); CD79a molecule; CD79a molecule, immunoglobulin-associated alpha; CD79A protein; CD79-alpha protein; EGK_10665; Ig alpha; IGA; Igalpha; ig-alpha; immunoglobulin-associated alpha; LOC100913063; Ly54; Ly-54; MB1; MB-1; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; surface IgM-associated protein | |
Mouse | |
100 μg | |
Primary | |
Human, Mouse | |
Antibody | |
IgG1 κ |
For Research Use Only.